Ashland did something neat on paper: it turned a massive operating loss into a small operating profit and more than doubled cash over the comparable period.
The numbers are stark. Revenue climbed 7.3% to $497.0M, gross profit rose to $170.0M, operating income swung from a -$708.0M loss to $43.0M, and cash jumped from $207.0M to $440.0M.
"The decrease was primarily driven by favorable price/mix, the divestiture of the Avoca business and lower operating costs, partially offset by higher volumes and unfavorable foreign currency."
Ashland / 10-Q / 2026-07-29
That is Ashland’s own headline explanation: price/mix gains and the sale of the Avoca business, plus lower operating costs, accounted for the improved margins. Put bluntly, part of the profit swing is a balance-sheet and portfolio story, not just a clean fix to manufacturing economics.
"The change in cash flows from operating activities from continuing operations was primarily driven by favorable working capital, including the favorable impact between periods of the U.S. and Foreign Accounts Receivable Sales Program activity."
Ashland / 10-Q / 2026-07-29
Ashland separately points at working-capital timing, specifically the U.S. and Foreign Accounts Receivable Sales Program, as the main driver of the cash jump. That helps explain why cash more than doubled even as accounts receivable on the balance sheet rose 27.4% year over year and inventory fell 13.6%.
The tension the filing leaves on the table is simple: headline profitability came from a mix of a portfolio sale, price/mix, and timing in receivables, while the company also discloses persistent operational pressure. The 10-Q adds that, "Excluding these key items... [results] was primarily driven by unfavorable production costs and higher selling, general and administrative expenses, partially offset by higher sales volumes, price/mix and foreign currency exchange." That sentence reads like an asterisk: core production costs and SG&A are still a drag once you strip out the one-offs.
That matters for liquidity and leverage. Ashland reported $440.0M of cash against a net debt position of $1.2B, and the company carries an enterprise value of $4.5B. The increase in cash provides near-term liquidity relief, but the filing ties a big part of that relief to a receivables program and to the Avoca divestiture rather than to a sustained drop in underlying costs.
Put another way, the quarter reduced the reported loss and boosted liquidity, but the filing flags two follow-ups investors should watch: whether favorable price/mix and the Avoca sale are repeatable, and whether production costs and SG&A actually trend lower when the timing effect of the AR program fades.
Will Ashland convert this quarter’s portfolio and timing gains into durable margin improvement once the Avoca-related effects and the AR sales timing are behind it?
Figures and quotations from Ashland Inc. 10-Q for the period ended 2026-06-30, filed 2026-07-29.